Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Placebo-Controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis.

X
Trial Profile

Double-Blind, Placebo-Controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vidutolimod (Primary)
  • Indications Hypersensitivity; Rhinoconjunctivitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 13 Jan 2009 Results from a subgroup analysis of patients with allergic asthma (52 out of 80 patients) have been reported in a Cytos Biotechnology media release; data from allergy diary entries were also reported.
    • 13 Jan 2009 Results have been presented at the 2008 meeting of American College of Allergy, Asthma and Immunology according to a Cytos Biotechnology media release.
    • 10 Jul 2008 Status changed from in progress to completed, based on results data reported in a Cytos media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top